ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

STIM Neuronetics Inc

3.81
0.31 (8.86%)
04 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Neuronetics Inc NASDAQ:STIM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.31 8.86% 3.81 3.60 5.02 3.86 3.50 3.59 41,783 05:00:00

Neuronetics to Report Fourth Quarter and Fiscal Year 2020 Financial and Operating Results and Host Conference Call

16/02/2021 12:00pm

GlobeNewswire Inc.


Neuronetics (NASDAQ:STIM)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Neuronetics Charts.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release fourth quarter and fiscal year 2020 financial and operating results, and certain guidance for the first quarter and full year 2021, prior to market open on Tuesday, March 2, 2021. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via a webcast on the Company’s investor relations website at ir.neuronetics.com. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 2124449, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.About NeuroneticsNeuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Additional information can be found at www.neuronetics.com.Investor Contact:Mark R. KlausnerWestwicke Partners443-213-0501ir@neuronetics.comMedia Contact:Chelsey MankoVault Communications610-455-2778cmanko@vaultcommunications.com

1 Year Neuronetics Chart

1 Year Neuronetics Chart

1 Month Neuronetics Chart

1 Month Neuronetics Chart

Your Recent History

Delayed Upgrade Clock